Prospective evaluation of 68Ga-DOTA-NOC PET-CT in patients with recurrent medullary thyroid carcinoma: Comparison with 18F-FDG PET-CT

Nuclear Medicine Communications

Volumn 33, Issue 7, 2012, Pages 766-774

  Naswa, Niraj ^a   Sharma, Punit ^a   Suman, Sudhir ^a   Lata, Sneh ^a   Kumar, Rakesh ^a   Malhotra, Arun ^a   Bal, Chandrasekhar ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

18F FDG; 68Ga DOTA NOC; medullary thyroid carcinoma; PET CT; recurrence

Indexed keywords

(1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID) 1 SODIUM TRIIODIDE OCTREOTIDE; CALCITONIN; FLUORODEOXYGLUCOSE F 18; GALLIUM 68; OCTREOTIDE; TETRAXETAN; UNCLASSIFIED DRUG; 68GA TETRAAZACYCLODODECANE TETRAACETIC ACID NAL(3) OCTREOTIDE; 68GA-TETRAAZACYCLODODECANE TETRAACETIC ACID-NAL(3)-OCTREOTIDE; DIAGNOSTIC AGENT; ORGANOMETALLIC COMPOUND; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ECHOGRAPHY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; QUALITATIVE RESEARCH; QUANTITATIVE STUDY; THYROID MEDULLARY CARCINOMA; LYMPH NODE; MEDULLARY CARCINOMA; METHODOLOGY; MIDDLE AGED; NECK; PROSPECTIVE STUDY; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; THYROID TUMOR; TUMOR RECURRENCE;

ADULT; AGED; CARCINOMA, MEDULLARY; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPH NODES; MALE; MIDDLE AGED; NECK; NEOPLASM RECURRENCE, LOCAL; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS;

EID: 84862182488     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e3283541157     Document Type: Article

References (31)

1. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 1998; 83:2638-2648.
2. Marsh DJ, Learoyd DL, Robinson BG. Medullary thyroid carcinoma: Recent advances and management update. Thyroid 1995; 5:407-424.
3. Leboulleux S, Baudin E, Travagli JP, Schlumberger M. Medullary thyroid carcinoma. Clin Endocrinol (Oxf) 2004; 61:299-310.
4. Dralle H, Damm I, Scheumann GF, Kotzerke J, Kupsch E. Frequency and significance of cervicomediastinal lymph node metastases in medullary thyroid carcinoma: Results of a compartment-oriented microdissection method. Henry Ford Hosp Med J 1992; 40:264-267.
5. Bergholm U, Adami HO, Bergstrom R, Johansson H, Lundell G, Telenius- Berg M, Akerström G. Clinical characteristics in sporadic and familial medullary thyroid carcinoma: A nationwide study of 249 patients in Sweden from 1959 through 1981. Cancer 1989; 63:1196-1204.
6. Scollo C, Baudin E, Travagli JP, Caillou B, Bellon N, Leboulleux S, et al. Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2003; 88:2070-2075.
7. Elisei R, Bottici V, Luchetti F, Di Coscio G, Romei C, Grasso L, et al. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: Experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab 2004; 89:163-168.
8. DeLellis RA, Rule AH, Spiler I, Nathanson L, Tashjian AH Jr., Wolfe HJ. Calcitonin and carcinoembryonic antigen as tumour markers in medullary thyroid carcinoma. Am J Clin Pathol 1978; 70:587-594.
9. Abdelmoumene N, Schlumberger M, Gardet P, Roche A, Travagli JP, Francese C, Parmentier C. Selective venous sampling catheterisation for localisation of persisting medullary thyroid carcinoma. Br J Cancer 1994; 69:1141-1144.
10. Crow JP, Azar-Kia B, Prinz RA. Recurrent occult thyroid carcinoma detected by MR imaging. Am J Roentgenol 1989; 152:1255-1256.
11. Schwerk WB, Grun R,Wahl R. Ultrasound diagnosis of C-cell carcinoma of the thyroid. Cancer 1985; 55:624-630.
12. Raue F,Winter J, Frank-Raue K, Lorenz D, Herfarth C, Ziegler R. Diagnostic procedure before reoperation in patients with medullary thyroid carcinoma. Horm Metab Res Suppl 1989; 21:31-34.
13. Dorr U, Wurstlin S, Frank-Raue K, Raue F, Hehrmann R, Iser G, et al. Somatostatin receptor scintigraphy and magnetic resonance imaging in recurrent medullary thyroid carcinoma: A comparative study. Horm Metab Res Suppl 1993; 27:48-55.
14. Clarke S, Lazarus C, Maisey M. Experience in imaging medullary thyroid carcinoma using 99mTc (V) dimercaptosuccinic acid (DMSA). Henry Ford Hosp Med J 1989; 37:167-168.
15. Ugur O, Kostakglu L, Guler N, Caner B, Uysal U, Elahi N, et al. Comparison of 99mTc(V)-DMSA, 201Tl and 99mTc-MIBI imaging in the follow-up of patients with medullary carcinoma of the thyroid. Eur J Nucl Med 1996; 23:1367-1371.
16. Gao Z, Biersack H, Ezziddin S, Logvinski T, An R. The role of combined imaging in metastatic medullary thyroid carcinoma: 111In-DTPA-octreotide and 131I/123I-MIBG as predictors for radionuclide therapy. J Cancer Res Clin Oncol 2004; 130:649-656.
17. Dietlein M, Scheidhauer K, Voth E, Theissen P, Schicha H. Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 wholebody scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 1997; 24:1342-1348.
18. Brandt MK, Muller SP, Gorges R, Saller B, Bockisch A. The value of fluorine- 18 fluorodeoxyglucose PET in patients with medullary thyroid cancer. Eur J Nucl Med 2000; 27:490-496.
19. Diehl M, Risse JH, Brandt-Mainz K, Dietlein M, Bohuslavizki KH, Matheja P, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: Results of a multicentre study. Eur J Nucl Med 2001; 28:1671-1676.
20. Lamberts SWJ, Krenning E, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 1991; 12:450-482.
21. Zatelli MC, Piccin D, Tagliati F, Bottoni A, Luchin A, Vignali C, et al. Selective activation of somatostatin receptor subtypes differentially modulates secretion and viability in human medullary thyroid carcinoma primary cultures: Potential clinical perspectives. J Clin Endocrinol Metab 2006; 91:2218-2224.
22. Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000; 27:273-282.
23. Zhernosekov KP, Filosofov DV, Baum RP, Aschoff P, Bihl H, Razbash AA, et al. Processing of generator-produced 68Ga for medical application. J Nucl Med 2007; 48:1741-1748.
24. Ong S, Schöder H, Patel S, Tabangay-Lim I, Doddamane I, Gönen M, et al. Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. J Nucl Med 2007; 48:501-507.
25. Szakáll SJ, Esik O, Bajzik G, Repa I, Dabasi G, Sinkovics I, et al. 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma. J Nucl Med 2002; 43:66-71.
26. De Groot J, Links T, Jager P, Kahraman T, Plukker J. Impact of 18F-fluoro-2- deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer. Ann Surg Oncol 2004; 11:786-794.
27. Musholt TJ, Musholt PB, Dehdashti F, Moley JF. Evaluation of fluorodeoxyglucose-positron emission tomographic scanning and its association with glucose transporter expression in medullary thyroid carcinoma and pheochromocytoma: A clinical and molecular study. Surgery 1997; 122:1049-1060.
28. Ambrosini V, Campana D, Bodei L, Nanni C, Castellucci P, Allegri V, et al. 68Ga-DOTA-NOC PET/CT clinical impact in patients with neuroendocrine tumors. J Nucl Med 2010; 51:669-673.
29. Campana D, Ambrosini V, Pezzilli R, Fanti S, Labate AM, Santini D, et al. Standardized uptake values of 68Ga-DOTA-NOC PET: A promising prognostic tool in neuroendocrine tumors. J Nucl Med 2010; 51: 353-359.
30. Bogsrud TV, Karantanis D, Nathan MA, Mullan BP, Wiseman GA, Kasperbauer JL, et al. The prognostic value of 2-deoxy-2-[18F]fluoro-Dglucose positron emission tomography in patients with suspected residual or recurrent medullary thyroid carcinoma. Mol Imaging Biol 2010; 12: 547-553.
31. Brendon GC, Nikolaos DP, Prakash V, Kayani I, Caplin M, Mahmood S, et al. Comparison of 68Ga-DOTATATE and 18F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2010; 37:49-57.